Zugriffe | |
---|---|
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program | 122 |
September 2023 | Oktober 2023 | November 2023 | Dezember 2023 | Januar 2024 | Februar 2024 | März 2024 | |
---|---|---|---|---|---|---|---|
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program | 0 | 7 | 3 | 0 | 1 | 8 | 3 |
Zugriffe | |
---|---|
2021_Frost_etal.pdf | 181 |